85-1778-18　(R)-Roscovitine 5mg　045188

特徴

• Potent and selective inhibitor of CDKs. More potent than olomoucine. Inhibits CDK1/cyclin B kinase (IC50 = 450nM), CDK2 (IC50 = 700nM) and CDK5/p35 (IC50 = 160nM). Inhibits M phase promoting factor (MPF) kinase activity. Arrests human fibroblasts in G1 phase. Antitumor compound. Activates the mitogen-activated protein kinase pathway. Targets both the p53 and NF-kappaB pathways. Has effects on calcium channel gating. Prevents DNA damage-induced cyclin A1 upregulation. Apoptosis inducer. As CYC202 in phase I clinical trials.
• Synonyms:(2R)-2-[[9-(1-methylethyl)-6-[(phenylmethyl)amino]-9H-purin-2-yl]amino]-1-butanol; (R)-2-[[9-(1-methylethyl)-6-[(phenylmethyl)amino]-9H-purin-2-yl]amino]-1-butanol; 2-(R)-(1-Ethyl-2-hydroxyethylamino)-6-benzylamino-9-isopropylpurine; CYC 202; (R)-Roscovitine; R-Roscovitine; Roscovitin; Seliciclib
• Molecular Weight:354.5
• Molecular Formula:C₁₉H₂₆N₆O
• Solubility:DMSO or 100% ethanol; only moderately soluble in water
• Appearance:Supplied as a white to off-white solid.
• Purity:≥98% (NMR)
• Storage and Stability:Store at 4°C. For maximum recovery of product, centrifuge the original vial prior to removing the cap.